Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: Significance for blood flow modification

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1955-1960

  Tozer, G M ^a   Prise, V E ^a   Bell, K M ^a   Dennis, M F ^a   Stratford, M R L ^a   Chaplin, D J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Endothelium derived relaxing factor; Isolated perfusion; Nitric oxide; Nitric oxide donors; P22 rat carcinosarcoma; Tumour vascular resistance

Indexed keywords

ACETYLCHOLINE; ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POTASSIUM CHLORIDE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; RAT; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0030443301     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.659     Document Type: Article

References (30)

1. ANDRADE SP, HARD IR AND PIPER PJ. (1992). Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br. J. Pharmacol., 107, 1092-1095.
2. BATES JN, BAKER MT, GUERRA R AND HARRISON DG. (1991). Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem. Pharmacol., 42, S157-S165.
3. BUTTERY LDK, SPRINGALL DR, ANDRADE SP, RIVEROS-MORENO V, HART I, PIPER PJ AND POLAK JM. (1993). Induction of nitric oxide synthase in neo-vasculature of experimental tumours in mice. J. Pathol., 171, 311-319.
4. CHAPLIN DJ. (1989). Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy. J. Natl Cancer Inst., 81, 618-622.
5. CHAPLIN DJ AND ACKER B. (1987). The effect of hydralazine on the tumor cytotoxicity of the cell cytotoxin RSU-1069: evidence for therapeutic gain. Int. J. Radiat. Oncol. Biol. Phys., 13, 579-585.
6. CHHATWAL VJS, NGOI SS, CHAN STF, CHIA YW AND MOOCHHALA SM. (1994). Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Carcinogenesis, 15, 2081-2085.
7. COBBS CS, BRENMAN JE, ALDAPE KD, BREDT DS AND ISRAEL MA. (1995). Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res., 55, 727-730.
8. DENEKAMP J AND HOBSON B. (1982). Endothelial cell proliferation in experimental tumours. Br. J. Cancer, 46, 711-720.
9. DVORAK HF, NAGY JA AND DVORAK AM. (1991). Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3, 77-85.
10. EVERETT SA, DENNIS MF, TOZER GM, PRISE VE, WARDMAN P AND STRATFORD MRL. (1995). Nitric oxide in biological fluids: analysis of nitrite and nitrate by high preformance ion chromatography. J Chromatog. A., 706, 437-442.
11. FEELISCH M. (1991). The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J. Cardiovasc. Pharmacol., 17, S25-S33.
12. FURCHGOTT RF AND ZAWADZKI JV. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
13. HORSMAN MR, CHRISTENSEN KL AND OVERGAARD J. (1992). Relationship between the hydralazine-induced changes in murine tumor blood flow supply and mouse blood pressure. Int. J. Radiat. Orcol. Bio. Phys., 22, 455-458.
14. JAIN RK AND WARD-HARTLEY K. (1984). Tumor blood flow characterisation, modifications and role in hyperthermia. IEEE Trans. SU-31, 504-526.
15. KENNOVIN GD, FLITNEY FW AND HIRST DG. (1994). 'Upstream' modification of vasoconstrictor responses in rat epigastric artery supplying an implanted tumour. In Oxygen Transport to Tissue XV. Vaupel P (ed.) pp. 411-416. Plenum Press: New York.
16. LEVICK JR. (1992). An Introduction to Cardiovascular Physiology, Butterworth-Heinemann Ltd: Oxford.
17. MARAGOS CM, WANG JM, HRABIE JA, OPPENHEIM JJ AND KEEFER IK. (1993). Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res., 53, 564-568.
18. PETERSON H-I. (1991). Modification of tumour blood flow a review. Int. J. Radiat. Biol., 60, 201-210.
19. POSTON L AND TAYLOR PD. (1995). Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci., 88, 245-255.
20. RALEVIC V AND BURNSTOCK G. (1993). Neural-Endothelial Interactions in the Control of Local Vascular Tone. RC Landes: Austin, TX, USA.
21. SAGAR SM, KLASSEN GA, BARCLAY KD AND ALDRICH JE, (1993). Tumour blood flow: measurement and manipulation for therapeutic gain. Cancer Treat. Rev., 19, 299-349.
22. STERNBERGH WC AND ADELMAN B. (1992). The temperol relationship between endothelial cell dysfunction and skeletal muscle damage after ischemia and reperfusion. J. Vasc. Surg., 16, 30-39.
23. STRATFORD MRL, DENNIS MF, TOZER GM, PRISE VE AND EVERETT SE. (1996). Measurement of nitric oxide in biological materials by high performance ion chromatography and EPR spectroscopy: a comparative study. In The Biology of Nitric Oxide Part 5. Moncada S et al. (eds) p. 175. Portland Press: London.
24. THOMSEN LL, LAWTON FG, KNOWLES RG, BEESLEY JE, RIVEROS-MORENO V AND MONCADA S. (1994). Nitric oxide synthase activity in human gynecological cancer. Cancer Res., 54, 1352-1354.
25. THOMSEN LL, MILES DW, HAPPERFIELD L, BOBROW LG, KNOWLES RG AND MONCADA S. (1995). Nitric oxide synthase activity in human breast cancer. Br. J. Cancer, 72, 41-44.
26. TOZER GM, SHAFFI KM, PRISE VE AND CUNNINGHAM VJ. (1994). Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br. J. Cancer, 70, 1040-1046.
27. TOZER GM, PRISE VE AND BELL KM. (1995). The influence of nitricoxide on tumour vascular tone. Acta Oncol., 34, 373-377.
28. WOOD P, STRATFORD IJ, ADAMS GE, SZABO C, THIEMERMANN C AND VANE JR. (1993). Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem. Biophys. Res. Commun., 192, 505-510.
29. G-nitro-L-arginine. Cancer Res., 54, 6458-6463.
30. ZYGMUNT PM, HÖGESTÄTT ED AND GRUNDEMAR L. (1994). Light-dependent effects of zinc protoporphyrin IX on endothelium-dependent relaxation resistant to Nω-nitro-L-arginine. Acta Physiol. Scand., 152, 137-143.